LY2127399

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Jun 1, 2011 → Feb 1, 2014

NCT ID

NCT01215942

About LY2127399

LY2127399 is a phase 3 stage product being developed by Eli Lilly for Rheumatoid Arthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01215942. Target conditions include Rheumatoid Arthritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01576549	Phase 2	Terminated	May 1, 2012	May 1, 2013	Rheumatoid Arthritis
NCT01215942	Phase 3	Terminated	Jun 1, 2011	Feb 1, 2014	Rheumatoid Arthritis
NCT01200290	Phase 2	Completed	Apr 1, 2011	Mar 1, 2014	Kidney Failure, Chronic
NCT01253291	Phase 1	Completed	May 1, 2010	Mar 1, 2014	Rheumatoid Arthritis
NCT00837811	Phase 2	Completed	Feb 1, 2009	Jan 1, 2012	Rheumatoid Arthritis
NCT00689507	Phase 1	Completed	Mar 1, 2008	May 1, 2014	Multiple Myeloma

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors

Product	Company	Stage	Hype Score
Tilmanocept	Navidea Biopharmaceuticals	Phase 1	25
Tc99m tilmanocept	Navidea Biopharmaceuticals	Phase 2	44
KPL-404 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid	Eli Lilly	Phase 3	77
Baricitinib + TNF Inhibitor	Eli Lilly	Approved	85
CT-P17 SC AI (adalimumab)	Celltrion	Phase 3	77
Remsima IV + Remsima SC	Celltrion	Pre-clinical	23
CT-P13 + Remicade	Celltrion	Phase 3	77
CT-P47 + EU-approved RoActemra	Celltrion	Phase 3	77
Infliximab	Celltrion	Phase 3	77
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
Rituximab, MTX, folic acid	Celltrion	Phase 1	33
CT-P10 + Rituxan + MabThera	Celltrion	Phase 3	77
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)	Celltrion	Phase 3	77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 3	77
rituximab	Celltrion	Phase 1	33
CT-P17 SC + Humira SC	Celltrion	Phase 3	77
Adalimumab	Celltrion	Pre-clinical	23
Infliximab	Celltrion	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Pre-clinical	23

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved